Heartflow, Inc.
Close on Oct 19, 2026
- Market cap
- $4.41B
- P/E (TTM)
- –
- Dividend yield
- –
About Heartflow
Surgical & Medical Instruments & Apparatus, SIC 3841
Heartflow develops artificial intelligence and computational software to provide non-invasive diagnostic and management solutions for coronary artery disease. The company's core offering, the Heartflow Platform, utilizes deep learning and computational fluid dynamics to construct personalized 3D anatomical models of coronary arteries from coronary computed tomography angiography scans. Key offerings include Heartflow RoadMap Analysis, which visualizes anatomy to streamline radiology workflows; Heartflow FFR CT Analysis, which evaluates fractional flow reserve and blood flow restrictions; and Heartflow Plaque Analysis, which characterizes plaque composition and volume. Its customer base consists of hospitals, outpatient imaging centers, and clinicians such as radiologists and cardiologists.
The enterprise maintains an installed base exceeding 1,465 accounts across the United States. Its corporate headquarters are not identified in the provided disclosure. International clinical studies have evaluated the technology across sites in Europe, the United Kingdom, Japan, Korea, Australia, and Canada, while research also references a Dutch study site.
Summary of the business section of Heartflow's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Heartflow, Inc.
- Founded
- 2007
- Headquarters
- San Francisco, CA
- Address
- 135 Main Street, Suite 1000 94105
- Phone
- (650) 241-1221
- Website
- www.heartflow.com
- Employees
- 843, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- HTFL
- Exchange
- Nasdaq
- IPO date
- Aug 8, 2025
- Shares outstanding
- 87M, Jul 31, 2026
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 1464521
- CUSIP
- 42238D107
- ISIN
- US42238D1072
- EIN
- 26-0506743
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John C.M. Farquhar | Chief Executive Officer, Director | 321,914 |
| Campbell Rogers | Chief Medical Officer | 244,328 |
| Vikram Verghese | Chief Financial Officer | 155,183 |
| Marie L. Jones | Chief Accounting Officer | 32,176 |
| Jeffrey C. Lightcap | Director | 6,991,237 |
| Timothy C. Barabe | Director | 188,231 |
| William C. Weldon | Director | 243,931 |
| Casey M. Tansey | Director | 3,187,509 |
| Wayne Joseph Riley | Director | – |
| Julie A. Cullivan | Director | 27,291 |
| Partners Management LP HealthCor | Director | 0 |
| Nicholas Downing | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 8, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 7, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jun 14, 2010 | Name change | Name changed from Cardiovascular Simulation, Inc. to Heartflow, Inc. |